A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

Inclusion Criteria: 1. Diagnosis of T2DM ≥ 6 months prior to screening 2. HbA1c level of 7-10% (inclusive) Exclusion Criteria: 1. Have known type 1 diabetes mellitus (T1DM) 2. History of severe hypoglycaemia defined as ≥ 2 episodes of severe hypoglycaemia within 6 months prior to screening 3. Have had ≥ 2 episodes of ketoacidosis or hyperosmolar state/coma requiring hospitalization in the 6 months prior to screening 4. Has fasting serum TG ≥ 500 mg/dL or 9 mmol/L at screening. 5. Patients receiving lipid-lowering therapy must have been on the same dose of therapy for the past three months